{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T14:33:54Z","timestamp":1794062034239,"version":"4.8.0"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2024,3,25]],"date-time":"2024-03-25T00:00:00Z","timestamp":1711324800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,5,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>MEK signaling pathway targeting has emerged as a valuable addition to the options available for the treatment of advanced cancers including melanoma and non-small cell lung cancer. Ophthalmologic monitoring of patients taking part in clinical trials of MEK inhibitors has shown that while ocular effects are common, generally emerging during the first days to weeks of treatment, the majority are either asymptomatic or have minimal visual impact and are benign, resolving without intervention or the need to reduce or stop MEK inhibitor therapy. However rare cases of serious, potentially vision-threatening ocular toxicities have been reported during MEK inhibitor therapy. There is currently no recommendation for routine ophthalmologic screening or monitoring of patients with advanced cancer who are initiating MEK inhibitor therapy. However, baseline ophthalmologic examination may be useful for all patients initiating MEK inhibitor therapy to allow the differentiation of preexisting pathology versus the development of MEK inhibitor-associated retinopathy in the event of the emergence of symptomatic ocular events. Regular ophthalmologic examination may be appropriate for patients at increased risk for ocular events, such as patients with a history of ocular inflammation, infection, or underlying macular\/retinal disease. All patients reporting visual disturbance should be referred for prompt ophthalmologic review to determine the potential seriousness of any underlying abnormalities and whether there is a need for treatment modification or specific intervention. Understanding the potential consequences of ocular toxicities is of particular importance in the context of decision-making for the continuation of potentially life-prolonging medications such as MEK inhibitors.<\/jats:p>","DOI":"10.1093\/oncolo\/oyae014","type":"journal-article","created":{"date-parts":[[2024,3,18]],"date-time":"2024-03-18T21:46:00Z","timestamp":1710798360000},"page":"e616-e621","source":"Crossref","is-referenced-by-count":40,"title":["Ocular Effects of MEK Inhibitor Therapy: Literature Review, Clinical Presentation, and Best Practices for Mitigation"],"prefix":"10.1093","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1382-4191","authenticated-orcid":false,"given":"Karen W","family":"Jeng-Miller","sequence":"first","affiliation":[{"name":"Ophthalmic Consultants of Boston , Boston, MA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miles A","family":"Miller","sequence":"additional","affiliation":[{"name":"Center for Systems Biology, Massachusetts General Hospital Research Institute , Boston, MA , USA"},{"name":"Department of Radiology, Massachusetts General Hospital and Harvard Medical School , Boston, MA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey S","family":"Heier","sequence":"additional","affiliation":[{"name":"Ophthalmic Consultants of Boston , Boston, MA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,3,25]]},"reference":[{"key":"2024050313082640500_CIT0001","first-page":"27","article-title":"MEK and the inhibitors: from bench to bedside","volume-title":"J Hematol Oncol.","author":"Akinleye","year":"2013"},{"key":"2024050313082640500_CIT0002","first-page":"S17","article-title":"The RAS\/RAF\/MEK\/ERK and the PI3K\/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches","volume-title":"Expert Opin Ther Targets.","author":"De Luca","year":"2012"},{"key":"2024050313082640500_CIT0003","first-page":"113","article-title":"The MAPK and AMPK signalings: interplay and implication in targeted cancer therapy","volume-title":"J Hematol Oncol.","author":"Yuan","year":"2020"},{"key":"2024050313082640500_CIT0004","first-page":"1194","article-title":"Nuclear ERK: mechanism of translocation, substrates, and role in cancer","volume-title":"Int J Mol Sci.","author":"Maik-Rachline","year":"2019"},{"key":"2024050313082640500_CIT0005","first-page":"1733","article-title":"Interference with ERK-dimerization at the nucleocytosolic interface targets pathological ERK1\/2 signaling without cardiotoxic side-effects","volume-title":"Nat Commun.","author":"Tomasovic","year":"2020"},{"key":"2024050313082640500_CIT0006","first-page":"1388","article-title":"BRAF inhibitors in thyroid cancer: clinical impact, mechanisms of resistance and future perspectives","volume-title":"Cancers (Basel).","author":"Crispo","year":"2019"},{"key":"2024050313082640500_CIT0007","volume-title":"MEKINIST\u00ae (Trametinib) Prescribing Information","author":"Novartis","year":"2020"},{"key":"2024050313082640500_CIT0008","volume-title":"COTELLIC\u00ae (Cobimetinib) Prescribing Information","author":"Genentech Inc","year":"2018"},{"key":"2024050313082640500_CIT0009","author":"Array BioPharma Inc","year":"2019"},{"key":"2024050313082640500_CIT0010","author":"KOSELUGO (selumetinib)","year":"2020"},{"key":"2024050313082640500_CIT0011","first-page":"60","article-title":"Risk of ophthalmic adverse effects in patients treated with MEK inhibitors: a systematic review and meta-analysis","volume-title":"Ophthalmic Res.","author":"Alves","year":"2017"},{"key":"2024050313082640500_CIT0012","first-page":"249","article-title":"MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study","volume-title":"Lancet Oncol.","author":"Ascierto","year":"2013"},{"key":"2024050313082640500_CIT0013","first-page":"1694","article-title":"Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations","volume-title":"N Engl J Med.","author":"Flaherty","year":"2012"},{"key":"2024050313082640500_CIT0014","first-page":"603","article-title":"Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial","volume-title":"Lancet Oncol.","author":"Dummer","year":"2018"},{"key":"2024050313082640500_CIT0015","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdz183.004","article-title":"BEACON CRC: a randomized, 3-arm, phase 3 study of encorafenib and cetuximab with or without binimetinib vs. choice of either irinotecan or FOLFIRI plus cetuximab in BRAF V600E\u2013mutant metastatic colorectal cancer","author":"Kopetz","year":"2019"},{"key":"2024050313082640500_CIT0016","first-page":"e000491","article-title":"Tolerability of BRAF\/MEK inhibitor combinations: adverse event evaluation and management","volume-title":"ESMO Open.","author":"Heinzerling","year":"2019"},{"key":"2024050313082640500_CIT0017","first-page":"197","article-title":"Emerging toxicities in the treatment of non-small cell lung cancer: ocular disorders","volume-title":"Cancer Treat Rev.","author":"Agustoni","year":"2014"},{"key":"2024050313082640500_CIT0018","first-page":"146","article-title":"Clinical features of serous retinopathy observed with cobimetinib in patients with BRAF-mutated melanoma treated in the randomized coBRIM study","volume-title":"J Transl Med.","author":"de la Cruz-Merino","year":"2017"},{"key":"2024050313082640500_CIT0019","first-page":"1435","article-title":"Ocular adverse events associated with MEK inhibitors","volume-title":"Retina.","author":"Mendez-Martinez","year":"2019"},{"key":"2024050313082640500_CIT0020","first-page":"998","article-title":"Ocular toxicities of MEK inhibitors and other targeted therapies","volume-title":"Ann Oncol.","author":"Stjepanovic","year":"2016"},{"key":"2024050313082640500_CIT0021","first-page":"1907","article-title":"Serous retinopathy associated with mitogen-activated protein kinase kinase inhibition (binimetinib) for metastatic cutaneous and uveal melanoma","volume-title":"Ophthalmology.","author":"van Dijk","year":"2015"},{"key":"2024050313082640500_CIT0022","first-page":"1788","article-title":"Clinical and morphologic characteristics of MEK inhibitor-associated retinopathy: differences from central serous chorioretinopathy","volume-title":"Ophthalmology.","author":"Francis","year":"2017"},{"key":"2024050313082640500_CIT0023","first-page":"855","article-title":"Subretinal fluid associated with MEK inhibitor use in the treatment of systemic cancer","volume-title":"JAMA Ophthalmol.","author":"Weber","year":"2016"},{"key":"2024050313082640500_CIT0024","first-page":"664","article-title":"Effect of inhibition of the FGFR-MAPK signaling pathway on the development of ocular toxicities","volume-title":"Cancer Treat Rev.","author":"van der Noll","year":"2013"},{"key":"2024050313082640500_CIT0025","first-page":"771","article-title":"MEK\/ERK pathway mediates UVB-induced AQP1 downregulation and water permeability impairment in human retinal pigment epithelial cells","volume-title":"Int J Mol Med.","author":"Jiang","year":"2009"},{"key":"2024050313082640500_CIT0026","first-page":"2803","article-title":"Aquaporin-1 channels in human retinal pigment epithelium: role in transepithelial water movement","volume-title":"Invest Ophthalmol Vis Sci.","author":"Stamer","year":"2003"},{"key":"2024050313082640500_CIT0027","first-page":"519","article-title":"PD0325901, a mitogen-activated protein kinase kinase inhibitor, produces ocular toxicity in a rabbit animal model of retinal vein occlusion","volume-title":"J Ocul Pharmacol Ther.","author":"Huang","year":"2009"},{"key":"2024050313082640500_CIT0028","first-page":"1874","article-title":"Endothelial ERK1\/2 signaling maintains integrity of the quiescent endothelium","volume-title":"J Exp Med.","author":"Ricard","year":"2019"},{"key":"2024050313082640500_CIT0029","first-page":"eaaz8521","article-title":"Efficient blockade of locally reciprocated tumor-macrophage signaling using a TAM-avid nanotherapy","volume-title":"Sci Adv.","author":"Wang","year":"2020"},{"key":"2024050313082640500_CIT0030","first-page":"1437","article-title":"Transient MEK inhibitor-associated retinopathy in metastatic melanoma","volume-title":"Ann Oncol.","author":"Urner-Bloch","year":"2014"},{"key":"2024050313082640500_CIT0031","first-page":"1758835920944359","article-title":"Risk factors for MEK-associated retinopathy in patients with advanced melanoma treated with combination BRAF and MEK inhibitor therapy","volume-title":"Ther Adv Med Oncol.","author":"Booth","year":"2020"},{"key":"2024050313082640500_CIT0032","first-page":"97","article-title":"Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course and management","volume-title":"Eur J Cancer.","author":"Gogas","year":"2019"},{"key":"2024050313082640500_CIT0033","first-page":"1003","article-title":"MEK inhibitors: a new class of chemotherapeutic agents with ocular toxicity","volume-title":"Eye (Lond).","author":"Duncan","year":"2015"},{"key":"2024050313082640500_CIT0034","first-page":"1005","article-title":"Bilateral subfoveal neurosensory retinal detachment associated with MEK inhibitor use for metastatic cancer","volume-title":"JAMA Ophthalmol.","author":"McCannel","year":"2014"},{"key":"2024050313082640500_CIT0035","first-page":"146","article-title":"Ocular toxicity due to trametinib and dabrafenib","volume-title":"BMC Ophthalmol.","author":"Sarny","year":"2017"},{"key":"2024050313082640500_CIT0036","first-page":"159","article-title":"MEK inhibitor-associated central retinal vein occlusion associated with hyperhomocysteinemia and MTHFR variants","volume-title":"Ocul Oncol Pathol.","author":"Francis","year":"2020"},{"key":"2024050313082640500_CIT0037","first-page":"800","article-title":"Correlation between retinal vein occlusion and cancer - a nationwide Danish cohort study","volume-title":"Acta Ophthalmol","author":"Toft-Petersen","year":"2018"},{"key":"2024050313082640500_CIT0038","first-page":"4816527","article-title":"Mystery of retinal vein occlusion: vasoactivity of the vein and possible involvement of endothelin-1","volume-title":"Biomed Res Int.","author":"Kida","year":"2017"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/29\/5\/e616\/57396245\/oyae014.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/29\/5\/e616\/57396245\/oyae014.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,3]],"date-time":"2024-05-03T09:08:51Z","timestamp":1714727331000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/29\/5\/e616\/7634634"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,25]]},"references-count":38,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,3,25]]},"published-print":{"date-parts":[[2024,5,3]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyae014","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,5,1]]},"published":{"date-parts":[[2024,3,25]]}}}